Using Torque Teno Virus levels to predict treatment response in lung cancer patients
Efficacy of Torque Teno Virus as a Biomarker for Predicting Treatment Response of Immune Checkpoint Inhibitor Therapy and Postoperative Outcome in NSCLC Patients - A Prospective Non-interventional Single-arm Study
This study is testing if measuring Torque Teno Virus levels in the blood can help predict how well lung cancer patients respond to a specific type of treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Vienna Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Vienna) |
| Trial ID | NCT06967532 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the potential of Torque Teno Virus (TTV) levels as a biomarker to predict treatment responses in patients with non-small cell lung cancer (NSCLC) undergoing immune checkpoint inhibitor therapy. By analyzing blood samples, the study aims to establish a correlation between TTV levels and patient outcomes, including treatment efficacy and postoperative complications. The research seeks to improve the management of NSCLC patients by providing a more reliable method for assessing treatment response compared to current imaging techniques, which can be misleading.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with histologically or cytologically verified stage II-IV NSCLC who are operable after neoadjuvant systemic therapy involving immune checkpoint inhibitors.
Not a fit: Patients with early-stage NSCLC or those not receiving immune checkpoint inhibitors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for NSCLC patients, improving their chances of successful outcomes.
How similar studies have performed: While the use of TTV as a biomarker is being explored in other contexts, its application in oncology, particularly for NSCLC and immune checkpoint inhibitors, is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Histologically or cytologically verified NSCLC stage II-IV (OMD) according to UICC TNM8 edition considered operable in curative intent after neoadjuvant systemic therapy containing immune checkpoint inhibition by local multidisciplinary tumor board (MDT) decision. ECOG \< or = 1 Staging with PET/CT and cMRI/CCT Written informed consent Exclusion Criteria: \-
Where this trial is running
Vienna
- Medical University of Vienna — Vienna, Austria (Recruiting)
Study contacts
- Study coordinator: Clemens Aigner, MD, MBA, FETCS
- Email: clemens.aigner@meduniwien.ac.at
- Phone: +43140400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.